Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
Open Access
- 24 May 2011
- journal article
- Published by Springer Science and Business Media LLC in BMC Clinical Pharmacology
- Vol. 11 (1), 5
- https://doi.org/10.1186/1472-6904-11-5
Abstract
Background Thiazolidinediones (TZDs), rosiglitazone (RGZ) and pioglitazone (PGZ) are widely used as hypoglycemic drugs in patients with type 2 diabetes mellitus. The aim of our study was to investigate the profile of adverse drug reactions (ADRs) related to TZDs and to investigate potential risk factors of these ADRs. Methods Type 2 diabetic patients were identified from the French Database of PharmacoVigilance (FPVD) between 2002 and 2006. We investigated ADR related to TZD, focusing on 4 ADR: edema, heart failure, myocardial infarction and hepatitis corresponding to specific WHO-ART terms. Results Among a total of 99,284 adult patients in the FPVD, 2295 reports concerned type 2 diabetic patients (2.3% of the whole database), with 161 (7%) exposed to TZDs. The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7.4% versus 0.8% and 0.1% respectively, p < 0.001) whereas the frequency of hepatitis was similar (5.9% versus 4%, NS). A multiple logistic regression model taking into account potential confounding factors (age, gender, drug exposure and co-morbidities) found that TZD exposure remained associated with heart failure and edema, but not with hepatitis or myocardial infarction. Conclusions Thiazolidinediones exposure is associated with an increased risk of edema and heart failure in patients with type 2 diabetes even when recommendations for use are respected. In contrast, the risk of hepatic reactions and myocardial infarction with this class of drugs seems to be similar to other hypoglycemic agents.Keywords
This publication has 29 references indexed in Scilit:
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or PioglitazoneJAMA, 2010
- Rosiglitazone RevisitedArchives of Internal Medicine, 2010
- How safe is the use of thiazolidinediones in clinical practice?Expert Opinion on Drug Safety, 2008
- Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986???2001)Drug Safety, 2005
- Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 DiabetesDiabetes Care, 2003
- Thiazolidinedione‐Induced EdemaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 DiabetesDiabetes Care, 2001
- Hepatotoxicity with ThiazolidinedionesDrug Safety, 2001
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000
- [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].1985